Table 1.

Basic information of the included literature.

Study	Year	Group (dose, mg)	No.	Female/Male	Age, yr	Outcome measures
01657370[13]	2012	Ub = 1	28	26/2	NA	①②③④⑤
		Ub = 10	26	22/4
		Ub = 25	28	23/5
		Ub = 50	28	26/2
		Ub = 100	27	18/9
		Placebo	28	25/3
voss2016[14]	2012	Ub = 1	138	95/12	39.6 ± 10.7	①②③④⑤
		Ub = 10	139	92/16	41.1 ± 10.9
		Ub = 25	139	91/13	41.4 ± 11.5
		Ub = 50	139	92/14	40.7 ± 12.3
		Ub = 100	139	90/12	41.9 ± 11.0
		Placebo	139	99/14	40.8 ± 11.4
Lipton2019[15]	2018	Ub = 25	561	501/60	41.6 ± 12.3	①②③④⑤
		Ub = 50	562	497/65	41.0 ± 12.4
		Placebo	563	494/69	41.5 ± 12.2
Dodick2019[16]	2017	Ub = 50	556	493/63	40.2 ± 12.0	①②③④⑤
		Ub = 100	557	479/78	40.7 ± 12.4
		Placebo	559	491/68	40.5 ± 12.2
Goadsby2019[17]	2018	Ub = 100	260	140/116	NA	①②③④⑤
		Placebo	256	141/119

NA = not available, Ub = ubrogepant; ① percentage of participants reporting pain relief at 2 h postdose; ② percentage of participant reporting absence of photophobia at 2 h postdose; ③ percentage of participants reporting absence of nausea at 2 h postdose; ④ percentage of participants reporting absence of phonophobia at 2 h postdose; ⑤ common adverse effects.